LUPIN - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 3.5
Show all parameters (20 more)
🧾 Trade Setup
I’d recommend a cautious approach with a buy price of 2,160 ₹. Initial target profit-taking level should be set at 2,200 ₹, reflecting the immediate momentum and a conservative upside estimate based on current volume. A stop loss order should be placed at 2,090 ₹ to protect against a reversal if the stock encounters selling pressure or broader market headwinds. This is a moderately bullish play dependent on sustained volume.
✅ Positive
The stock is exhibiting strong momentum with a significant PAT growth of 27.6% QoQ and a robust ROCE of 26.2%. Furthermore, the RSI reading of 35.1 indicates relatively low overbought conditions, suggesting potential for further upside today if volume continues to support the move.
⚠️ Limitation
The stock’s P/E ratio is lower than the industry average (14.9 vs 34.8), which implies a discount valuation and possibly presents a risk of disappointment if growth doesn't maintain its current trajectory or if broader market sentiment shifts negatively. Increased DII holding (-0.67%) suggests underlying selling pressure, adding to this concern.
📉 Company Negative News
Recent news indicates that Lupin is down for the fifth straight session (Business Standard), which isn’t a positive sign given the recent strong performance and an FDA form 483 received for their Somerset facility (scanx.trade).
📈 Company Positive News
The share price rose 2.04% as valuation, peers and sector indicated a positive sentiment – Univest.
🏭 Industry
The pharmaceutical sector is currently experiencing mixed investor sentiment due to regulatory pressures and competition, however Lupin's recent profitability and robust growth metrics provide some support within this wider context.